血管紧张素转化酶2
发病机制
下调和上调
冠状病毒
肾素-血管紧张素系统
肺
血管紧张素II
平衡
医学
免疫学
受体
2019年冠状病毒病(COVID-19)
生物
内科学
疾病
基因
传染病(医学专业)
血压
生物化学
作者
Xiang Gao,Shengyuan Zhang,Jizhou Gou,Yanling Wen,Lujie Fan,Jian Zhou,Guangde Zhou,Gang Xu,Zheng Zhang
标识
DOI:10.1016/j.jinf.2022.06.030
摘要
The ongoing global pandemic of Coronavirus disease 2019 (COVID-19) poses a serious threat to human health, with patients reportedly suffering from thrombus, vascular injury and coagulation in addition to acute and diffuse lung injury and respiratory diseases. Angiotensin converting enzyme 2 (ACE2) as the receptor for SARS-CoV-2 entry, is also an important regulator of renin-angiotensin system (RAS) homeostasis, which plays an unsettled role in the pathogenesis of COVID-19. Here, we demonstrated that SARS-CoV-2 Spike protein activated intracellular signals to degrade ACE2 mRNA. The decrease of ACE2 and higher level of angiotensin (Ang) II were verified in COVID-19 patients. High dose of Ang II induced pulmonary artery endothelial cell death in vitro, which was also observed in the lung of COVID-19 patients. Our finding indicates that the downregulation of ACE2 potentially links COVID-19 to the imbalance of RAS.
科研通智能强力驱动
Strongly Powered by AbleSci AI